Press Releases

 
Press Releases
  Date Title View
Mar 23, 2017
CAMBRIDGE, Mass., March 23, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the enrollment of its first patient in a Phase 1 study of MM-310 in solid tumors. MM-310 is an antibody-directed nanotherapeutic (ADN) that encapsulates a novel taxane and targets the EphA2 receptor, a protein which surveys suggest is ove...
Mar 1, 2017
CAMBRIDGE, Mass., March 1, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced its fourth quarter and full year 2016 financial results for the period ended December 31, 2016. Key Recent Events As announced on January 8, 2017, Merrimack entered into an asset purchase and sale agreement with Ipsen S....
Feb 22, 2017
CAMBRIDGE, Mass., Feb. 22, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its Fourth Quarter 2016 investor conference call and webcast at 8:30 a.m., Eastern time, on Wednesday, March 1.    The call will cover an update on Merrimack's r...
Jan 18, 2017
CAMBRIDGE, Mass., Jan. 18, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) ("Merrimack" or the "Company") today announced that Richard Peters, M.D., Ph.D., has been appointed as the Company's President and Chief Executive Officer, effective February 6, 2017, at which time he will also be appointed to the Merrimack Board of Direc...
Jan 8, 2017
CAMBRIDGE, Mass., Jan. 8, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) ("Merrimack" or the "Company") today announced that it has entered into a definitive asset purchase and sale agreement with Ipsen (Euronext: IPN; ADR: IPSEY) for a transaction valued at up to $1.025 billion, plus up to $33 million in net milestone payments...
Jan 4, 2017
CAMBRIDGE, Mass., Jan. 4, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 11, 2017, at 3:00 PM Pacific Time. A live webcast of the presentation will be available in the Investors sec...
Dec 21, 2016
CAMBRIDGE, Mass., Dec. 21, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that, following a recent independent Data and Safety Monitoring Board (DSMB) recommendation and subsequent futility analysis, it has decided to stop the Phase 2 HERMIONE study of MM-302 (HER2 antibody-targeted liposomal doxorubicin) in HER...
Nov 9, 2016
CAMBRIDGE, Mass., Nov. 9, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced its third quarter 2016 financial results. Merrimack will host a live conference call and webcast today, Wednesday, November 9 at 4:30 p.m., Eastern time, to provide an update on Merrimack's progress as well as a summary of these results. ...
Nov 2, 2016
CAMBRIDGE, Mass., Nov. 2, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its Third Quarter 2016 investor conference call and webcast at 4:30 p.m., Eastern time, on Wednesday, November 9.    The call will cover an update on Merrimack's recent progress as well as a summary of thir...
Oct 31, 2016
CAMBRIDGE, Mass., Oct. 31, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for generic doxorubicin hydrochloride (HCI) liposome injection submitted by its partner Actavis LLC (an indirect, wholly o...
1
...
NextLast
= add release to Briefcase

In this section, you will find several of Merrimack’s high-resolution images. All images here are copyrighted by Merrimack Pharmaceuticals, Inc., and are made available here for editorial use only. By downloading and/or using any of the Merrimack’s images, you acknowledge the rights of Merrimack’s images, and you agree to comply with the usage guidelines.

X

Accept | Decline